article thumbnail

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Pharmaceutical Technology

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Allergies 299
article thumbnail

Groundbreaking mRNA Therapy Appears To Prevent and Treat Peanut Allergies in Mice

AuroBlog - Aurous Healthcare Clinical Trials blog

More treatments – and faster-acting treatments – for peanut allergies are urgently needed, and a new study outlines a promising drug technology based around a tiny nanoparticle just a few billionths of a meter in size. In tests on mice, the nanoparticle reversed peanut allergies and prevented them from developing in the first place.

Allergies 179
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nestle gives up on peanut allergy treatment after sluggish sales

Bio Pharma Dive

The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

article thumbnail

Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia

Fierce Pharma

billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. After lackluster sales dampened the initial enthusiasm that came with a $2.1

article thumbnail

DBV sets course on regulatory journey for peanut allergy patch

Pharmaceutical Technology

Following a tumultuous development cycle, DBV Technologies will now have to conduct an additional safety study of its peanut allergy Viaskin patch in toddlers ages 1–3 years, based on written correspondence from the US Food and Drug Administration (FDA). However, the French company will not be required to run a further efficacy study.

Allergies 130
article thumbnail

Top 3 Allergy Friendly Food Brands

XTalks

According to the Asthma and Allergy Foundation of America, about 32 million people in the US have food allergies, which means allergy friendly food brands not only have a large audience base, but are also necessities. Partake Foods has become one of the most popular allergy friendly food brands and it recently secured $11.5

article thumbnail

Black, Hispanic severe allergy patients less likely to receive allergy shots

Medical Xpress

Black and Hispanic patients with severe allergies are less likely to get a common treatment, allergen immunotherapy, compared to white patients, according to Penn State College of Medicine researchers.